HER2-negative Metastatic Breast Cancer Clinical Trial
Official title:
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
This was an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and PK of IV administered DAN-222 followed by a dose-escalation of DAN-222 in combination with niraparib: - Part A is dose escalation of single agent DAN-222 - Part B is dose escalation of DAN-222 in combination with niraparib
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03430518 -
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
|
Phase 1 | |
| Completed |
NCT01520103 -
Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
|
Phase 2 | |
| Completed |
NCT01619111 -
DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs
|
Phase 3 | |
| Completed |
NCT02605915 -
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT05362760 -
Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
|
Phase 4 | |
| Recruiting |
NCT04720729 -
Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer
|
Phase 2 |